(Q53098600)

English

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

Ladislav Dušek

10

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

11

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

author name string

Alexandr Poprach

1

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Tomas Pavlik

2

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Bohuslav Melichar

3

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Katerina Kubackova

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Zbynek Bortlicek

5

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Marek Svoboda

6

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Radek Lakomy

7

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Rostislav Vyzula

8

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Igor Kiss

9

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Czech Renal Cancer Cooperative Group

12

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

publication date

8 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

32

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

4

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

488-495

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

High CXCR4 expression correlates with sunitinib poor response in metastatic renal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2013.09.011

7 January 2021

Identifiers

10.1016/J.UROLONC.2013.09.011

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/24321257

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53098600&oldid=1531325136"